Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis

NCT04368806 is registered in ClinicalTrials.gov with Nature Cell Co. Ltd. as lead sponsor.

NCT NCT04368806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04368806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis
Lead sponsor
Nature Cell Co. Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 26, 2021
Completion date
August 7, 2027
Enrollment
173 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee